A patient with alcohol use disorder is started on gabapentin. What is the primary evidence-based rationale for this medication in this context?
-
A
It directly blocks alcohol receptors in the brain
-
B
It reduces alcohol craving and withdrawal symptoms by modulating calcium channels and glutamate
-
C
It is an FDA-approved first-line pharmacotherapy for AUD
-
D
It increases acetaldehyde levels to deter drinking